YAP1 and Hyperglycemia: Further the investigation revealed that inhibition of the ERK 1/2 signaling cascade reduced YAP1/TAZ expression, suggesting a potential therapeutic strategy to mitigate hyperglycemia-induced cardiovascular damage and inflammation [1, 12].